Sumanta K. Pal

34.0k total citations · 4 hit papers
741 papers, 17.4k citations indexed

About

Sumanta K. Pal is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Sumanta K. Pal has authored 741 papers receiving a total of 17.4k indexed citations (citations by other indexed papers that have themselves been cited), including 488 papers in Pulmonary and Respiratory Medicine, 311 papers in Oncology and 259 papers in Molecular Biology. Recurrent topics in Sumanta K. Pal's work include Renal cell carcinoma treatment (379 papers), Cancer Genomics and Diagnostics (219 papers) and Bladder and Urothelial Cancer Treatments (169 papers). Sumanta K. Pal is often cited by papers focused on Renal cell carcinoma treatment (379 papers), Cancer Genomics and Diagnostics (219 papers) and Bladder and Urothelial Cancer Treatments (169 papers). Sumanta K. Pal collaborates with scholars based in United States, Canada and France. Sumanta K. Pal's co-authors include Toni K. Choueiri, Robert A. Figlin, Brian I. Rini, Elizabeth R. Plimack, Nazlı Dizman, Hua Yu, Ulka N. Vaishampayan, Mark D. Pegram, David F. McDermott and Daniel Y.C. Heng and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Sumanta K. Pal

692 papers receiving 17.2k citations

Hit Papers

Nivolumab in metastatic u... 2016 2026 2019 2022 2017 2016 2017 2021 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
    2017 1.2k citations Padmanee Sharma, Andrea Necchi et al. profile →
  2. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study
    2016 371 citations Sumanta K. Pal et al. Journal of Clinical Oncology profile →
  3. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
    2017 348 citations Hans J. Hammers, Elizabeth R. Plimack et al. Journal of Clinical Oncology profile →
  4. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
    2021 170 citations Sumanta K. Pal, Daniel Y.C. Heng et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Sumanta K. Pal 8.7k 8.0k 6.9k 4.4k 4.2k 741 17.4k
Jennifer J. Knox 8.3k 0.9× 7.7k 1.0× 4.7k 0.7× 3.9k 0.9× 4.4k 1.1× 382 17.5k
Bohuslav Melichar 6.7k 0.8× 6.3k 0.8× 5.4k 0.8× 3.8k 0.9× 1.5k 0.4× 503 13.2k
Jacek Jassem 8.0k 0.9× 11.4k 1.4× 4.8k 0.7× 3.9k 0.9× 3.3k 0.8× 523 19.9k
Camillo Porta 12.2k 1.4× 7.0k 0.9× 10.0k 1.4× 5.8k 1.3× 2.3k 0.6× 576 21.1k
Jaafar Bennouna 7.8k 0.9× 14.4k 1.8× 3.6k 0.5× 3.6k 0.8× 2.9k 0.7× 340 18.3k
Luis Paz‐Ares 11.4k 1.3× 13.2k 1.7× 7.6k 1.1× 4.2k 1.0× 2.3k 0.6× 690 23.0k
Paul Elson 5.6k 0.6× 4.7k 0.6× 4.5k 0.6× 2.6k 0.6× 3.2k 0.8× 334 13.4k
Primo N. Lara 8.5k 1.0× 7.0k 0.9× 6.0k 0.9× 3.5k 0.8× 1.5k 0.4× 458 16.3k
Ezra E.W. Cohen 5.6k 0.6× 8.5k 1.1× 4.7k 0.7× 2.0k 0.4× 3.2k 0.8× 421 16.9k
Julian R. Molina 8.2k 0.9× 10.5k 1.3× 6.2k 0.9× 3.3k 0.7× 1.4k 0.3× 216 18.3k

Countries citing papers authored by Sumanta K. Pal

Since Specialization
Citations

This map shows the geographic impact of Sumanta K. Pal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sumanta K. Pal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sumanta K. Pal more than expected).

Fields of papers citing papers by Sumanta K. Pal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sumanta K. Pal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sumanta K. Pal. The network helps show where Sumanta K. Pal may publish in the future.

Co-authorship network of co-authors of Sumanta K. Pal

This figure shows the co-authorship network connecting the top 25 collaborators of Sumanta K. Pal. A scholar is included among the top collaborators of Sumanta K. Pal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sumanta K. Pal. Sumanta K. Pal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Pal, Sumanta K., et al.. (2024). The gut microbiome and dietary metabolites in the treatment of renal cell carcinoma. Urologic Oncology Seminars and Original Investigations. 43(4). 244–253. 3 indexed citations
3.
Egelston, Colt A., Susan E. Yost, Paul Frankel, et al.. (2024). A phase I/II trial of palbociclib, pembrolizumab, and endocrine therapy for patients with HR+/HER2- locally advanced or metastatic breast cancer (MBC): Clinical outcomes and stool microbial profiling.. Journal of Clinical Oncology. 42(16_suppl). 1038–1038. 1 indexed citations
4.
Agarwal, Neeraj, Arun Azad, Joan Carles, et al.. (2024). CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(4_suppl). 18–18. 20 indexed citations
5.
Pal, Sumanta K., Melissa A. Reimers, Benjamin Garmezy, et al.. (2024). A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9–engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS2676–TPS2676. 4 indexed citations
6.
7.
Barragán-Carrillo, Regina, et al.. (2023). Managing Metastatic Renal Cell Carcinoma after Progression on Immunotherapy. Hematology/Oncology Clinics of North America. 37(5). 965–976. 4 indexed citations
8.
Yang, Eddy S., Amin H. Nassar, Elio Adib, et al.. (2021). Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent. Molecular Cancer Therapeutics. 20(8). 1454–1461. 6 indexed citations
9.
Wells, J. Connor, Shaan Dudani, Gan Chen, et al.. (2020). Real-world clinical effectiveness of second-line sunitinib following immuno-oncology therapy in patients with metastatic renal cell carcinoma. European Urology Open Science. 19. e1105–e1106. 1 indexed citations
10.
Chen, Gan, Daniel E. Meyers, Igor Stukalin, et al.. (2020). 425P The impact of obesity on treatment outcomes in patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents. Annals of Oncology. 31. S1408–S1408. 2 indexed citations
11.
Martini, Alberto, Rachel Jia, Bart S. Ferket, et al.. (2019). Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancer. Cancer. 125(18). 3155–3163. 26 indexed citations
12.
Tannir, Nizar M., Sumanta K. Pal, & Michael B. Atkins. (2018). Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review. The Oncologist. 23(5). 540–555. 55 indexed citations
13.
14.
Hammers, Hans J., Elizabeth R. Plimack, Jeffrey R. Infante, et al.. (2017). Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. Journal of Clinical Oncology. 35(34). 3851–3858. 348 indexed citations breakdown →
15.
Hurria, Arti, Chie Akiba, Jérôme H. Kim, et al.. (2016). Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With Cancer. Journal of Oncology Practice. 12(12). e1025–e1034. 65 indexed citations
16.
Hossain, Dewan Md Sakib, Sumanta K. Pal, Dayson Moreira, et al.. (2015). TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients. Clinical Cancer Research. 21(16). 3771–3782. 156 indexed citations
17.
Pal, Sumanta K., Xiwei Wu, Hanjun Qin, et al.. (2015). Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Tyrosine Kinase Inhibitors. Clinical Cancer Research. 21(23). 5286–5293. 60 indexed citations
18.
Pal, Sumanta K., Miaoling He, Tommy R. Tong, et al.. (2014). RNA-seq Reveals Aurora Kinase–Driven mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. Molecular Cancer Research. 13(1). 130–137. 37 indexed citations
19.
Schroeder, Anne, Andreas Herrmann, Gregory Cherryholmes, et al.. (2013). Loss of Androgen Receptor Expression Promotes a Stem-like Cell Phenotype in Prostate Cancer through STAT3 Signaling. Cancer Research. 74(4). 1227–1237. 156 indexed citations
20.
Hong, Xin, Andreas Herrmann, Karen L. Reckamp, et al.. (2011). Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480. Cancer Research. 71(21). 6601–6610. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jennifer J. Knox Breakdown of academic impact, for papers by Bohuslav Melichar Breakdown of academic impact, for papers by Jacek Jassem Breakdown of academic impact, for papers by Camillo Porta Breakdown of academic impact, for papers by Jaafar Bennouna Breakdown of academic impact, for papers by Luis Paz‐Ares Breakdown of academic impact, for papers by Paul Elson Breakdown of academic impact, for papers by Primo N. Lara Breakdown of academic impact, for papers by Ezra E.W. Cohen Breakdown of academic impact, for papers by Julian R. Molina
Rankless by CCL
2026